Proton pump inhibitors and their drug interactions: an evidence-based approach

被引:61
作者
Gerson, LB [1 ]
Triadafilopoulos, G [1 ]
机构
[1] Stanford Univ, Med Ctr, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA
关键词
CYP450; drug interactions; lansoprazole; omeprazole; pantoprazole; proton pump inhibitors; rebeprazole;
D O I
10.1097/00042737-200105000-00025
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The proton pump inhibitors (PPIs) are the most effective antisecretory agents used to treat acid-related disorders, As such, they are frequently prescribed for patients who are concurrently using other medications, PPIs may interact with other drugs through numerous mechanisms. The most important include competitive inhibition of hepatic cytochrome P (CYP) 450 enzymes involved in drug metabolism, and alteration of the absorption of other drugs via changes in gastric pH levels, Poor metabolizers, who lack CYP2C19, may be particularly predisposed to drug interactions, Although the potential for drug interactions is high, few clinically significant interactions have been reported for the PPIs, Nevertheless, caution is indicated when certain drugs are co-prescribed with these agents, The incidence of clinically significant drug interactions increases proportionately with the number of drugs taken and with the age of the patient, The drug interaction with the greatest clinical importance is the reduction in benzodiazepine clearance by omeprazole, Eur J Gastroenterol Hepatol 13:611-616 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:611 / 616
页数:6
相关论文
共 73 条
[61]   THE CLINICAL IMPORTANCE OF DRUG-INTERACTIONS WITH ANTIULCER THERAPY [J].
REYNOLDS, JC .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1990, 12 :S54-S63
[62]   EFFECT OF OMEPRAZOLE ON GASTRIC 1ST-PASS METABOLISM OF ETHANOL [J].
ROINE, R ;
HERNANDEZMUNOZ, R ;
BARAONA, E ;
GREENSTEIN, R ;
LIEBER, CS .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (06) :891-896
[63]  
SCHOULER L, 1991, AM J GASTROENTEROL, V86, P1097
[64]  
Schulz HU, 1996, INT J CLIN PHARM TH, V34, pS51
[65]   THE H+,K+-ATPASE INHIBITOR PANTOPRAZOLE (BY1023/SK-AND-F96022) INTERACTS LESS WITH CYTOCHROME-P450 THAN OMEPRAZOLE AND LANSOPRAZOLE [J].
SIMON, WA ;
BUDINGEN, C ;
FAHR, S ;
KINDER, B ;
KOSKE, M .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (02) :347-355
[66]   INCIDENCE OF S-MEPHENYTOIN HYDROXYLATION DEFICIENCY IN A KOREAN POPULATION AND THE INTERPHENOTYPIC DIFFERENCES IN DIAZEPAM PHARMACOKINETICS [J].
SOHN, DR ;
KUSAKA, M ;
ISHIZAKI, T ;
SHIN, SG ;
JANG, IJ ;
SHIN, JG ;
CHIBA, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (02) :160-169
[67]   INFLUENCE OF SINGLE-DOSE AND MULTIPLE-DOSE OMEPRAZOLE TREATMENT ON NIFEDIPINE PHARMACOKINETICS AND EFFECTS IN HEALTHY-SUBJECTS [J].
SOONS, PA ;
VANDENBERG, G ;
DANHOF, M ;
VANBRUMMELEN, P ;
JANSEN, JBMJ ;
LAMERS, CBHW ;
BREIMER, DD .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (03) :319-324
[68]   STEREOSELECTIVE INTERACTION OF OMEPRAZOLE WITH WARFARIN IN HEALTHY-MEN [J].
SUTFIN, T ;
BALMER, K ;
BOSTROM, H ;
ERIKSSON, S ;
HOGLUND, P ;
PAULSEN, O .
THERAPEUTIC DRUG MONITORING, 1989, 11 (02) :176-184
[69]   CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori [J].
Tanigawara, Y ;
Aoyama, N ;
Kita, T ;
Shirakawa, K ;
Komada, F ;
Kasuga, M ;
Okumura, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (05) :528-534
[70]   A STUDY OF THE INTERACTION OF OMEPRAZOLE AND WARFARIN IN ANTICOAGULATED PATIENTS [J].
UNGE, P ;
SVEDBERG, LE ;
NORDGREN, A ;
BLOM, H ;
ANDERSSON, T ;
LAGERSTROM, PO ;
IDSTROM, JP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (06) :509-512